|
Cerezo-Manchado JJ, Roldan V, Rosafalco M, Anton AI, Arroyo AB, Garcia-Barbera N, Martínez AB, Padilla J, Corral J, Vicente V, Gonzalez-Conejero R. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014 May;15(7):987-96. doi: 10.2217/pgs.13.232. PubMed PMID: 24956252.
AÑO: 2014; IF: 3.218
|
24956252
|
Cerezo-Manchado JJ, Roldán V, Corral J, Rosafalco M, Antón AI, Padilla J, Vicente V, González-Conejero R. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. Thromb Haemost. 2016 Jan;115(1):117-25. doi: 10.1160/TH14-09-0814. Epub 2015 Nov 5. PubMed PMID: 26538428.
AÑO: 2016; IF: 5.627
|
|
de la Morena-Barrio ME, García A, Martínez-Martínez I, Miñano A, Padilla J, Navarro-Fernández J, Roldán V, Águila S, Iniesta JA, Corral J, Vicente V. A new method to quantify ?-antithrombin glycoform in plasma reveals increased levels during the acute stroke event. Thromb Res. 2015 Sep;136(3):634-41. doi: 10.1016/j.thromres.2015.06.039. PubMed PMID: 26186963.
AÑO: 2015; IF: 3.944
|
|
Corral J, Vicente V. Puzzling questions on antithrombin: Diagnostic limitations and real incidence in venous and arterial thrombosis. Thromb Res. 2015 Jun;135(6):1047-8. doi: 10.1016/j.thromres.2015.04.012. PubMed PMID: 25910517.
AÑO: 2015; IF: 2.32
|
|
Martínez-Martínez I, González-Porras JR, Cebeira MJ, de Arriba F, Espín S, Bohdan N, Corrales FJ, Corral J, Vicente V. Identification of a new potential mechanism responsible for severe bleeding in myeloma: immunoglobulins bind the heparin binding domain of antithrombin activating this endogenous anticoagulant. Haematologica. 2016 Oct;101(10):e423-e426. Epub 2016 Jun 16. PubMed PMID: 27479819; PubMed Central PMCID: PMC5046666.
AÑO: 2016; IF: 7.702
|